In the fully adjusted model for the full cohort in this study, prescription of a statin medication was associated with a lower risk of prostate cancer mortality (HR, 0.74; 95% CI, 0.67–0.82), whereas the use of exogenous insulin only (with no oral, antihyperglycemic medication) was associated with an increased risk of prostate cancer death (HR, 1.23; 95% CI, 1.05–1.45). This evidence concerns the gene INS and prostate carcinoma.